Smith & Nephew Rating Reiterated by Barclays (SN)
Smith & Nephew (LON:SN)‘s stock had its “equal weight” rating reiterated by equities research analysts at Barclays in a research note issued to investors on Tuesday, Analyst Ratings.Net reports. They currently have a GBX 780 ($12.82) price objective on the stock. Barclays’ price objective would suggest a potential downside of 11.96% from the stock’s previous close.
A number of other analysts have also recently weighed in on SN. Analysts at UBS AG reiterated a “buy” rating on shares of Smith & Nephew in a research note to investors on Tuesday. They now have a GBX 1,000 ($16.43) price target on the stock. Separately, analysts at Goldman Sachs Group Inc. reiterated a “sell” rating on shares of Smith & Nephew in a research note to investors on Tuesday. Finally, analysts at Societe Generale reiterated a “sell” rating on shares of Smith & Nephew in a research note to investors on Monday. They now have a GBX 660 ($10.85) price target on the stock. Three research analysts have rated the stock with a sell rating, ten have issued a hold rating and six have assigned a buy rating to the stock. Smith & Nephew currently has an average rating of “Hold” and an average price target of GBX 845.07 ($13.89).
Smith & Nephew (LON:SN) opened at 879.50 on Tuesday. Smith & Nephew has a one year low of GBX 692.592 and a one year high of GBX 897.00. The stock’s 50-day moving average is GBX 868.9 and its 200-day moving average is GBX 810.2. The company’s market cap is £7.907 billion.
Smith & Nephew plc is a global medical devices business operating in the markets for orthopaedic reconstruction and trauma, endoscopy (LON:SN) and advanced wound management.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.